Prevotella copri as Next Generation Probiotics

Creative Biolabs has expanded our strain collection for next-generation probiotics (NGPs) from the human microbiome. We guarantee that our global clients will get high-quality and high-safety Prevotella copri for production and formulation into commercial products. We are more than happy to share our extensive experience and help our customers with this extremely important step in the development of NGP.

Introduction of P. copri

P. copri is a gram-negative bacteri, belonging to the phylum Bacteroidetes. The cells are anaerobic and do not form spores. P. copri is a frequent inhabitant of the human intestinal microbiome that has been both positively and negatively associated with host health. Its anaerobic qualities allow it to grow successfully in the human gut and intestines. Studies have shown that P. copri is 39.1% prevalent in healthy individuals from metagenomic profiles.

Prevotella copri

Background of P. copri as a Potential NGP

Studies on the role of gut commensal bacteria in health development have rapidly attracted much more attention beyond the classical pathogens over the last decade. The strategy of modulating the structure of the gut microbiota has been under intensive study and shed more light on the amelioration of inflammation-related diseases, cancer, and neurodegenerative diseases. While traditional probiotics generally show marginal ameliorative effects, emerging NGPs start to reveal as new preventive and therapeutic tools.

As a potential NGP, P. copri was found to improve glucose homeostasis via intestinal gluconeogenesis. Besides, P. copri is also reported to involve exacerbation of glucose tolerance and enhance insulin resistance which occurs before the development of type 2 diabetes and ischaemic cardiovascular disease. Moreover, studies have shown a correlation between P. copri and the development of rheumatoid arthritis (RA). P. copri has been identified as highly enriched in the gut microbiota of patients with RA and an increased immune response to this organism has been demonstrated in those patients. Generally, P. copri strains may work as a beneficial bacterium, which needs further investigation.

Phylogenetic representation of all 1,023 P. copri genomes separated for each clade of the P. copri complex. Fig.1 Phylogenetic representation of all 1,023 P. copri genomes separated for each clade of the P. copri complex. (Tett, 2019)

Development of P. copri as a Potential NGP at Creative Biolabs

With years of experience in the research of NGPs, scientists at Creative Biolabs have paid close attention to the discovery of beneficial Bacteroides strains, exploring their interaction mechanisms with the host, and evaluating the potential safety risks during commercialization. We have perfected our technical pipelines in the development of P. copri as a potential NGP. We would like to share our knowledge and passion in this field to facilitate our customers' research and project development.

Highlights

  • The whole process is performed under GMP conditions
  • Large-scale fermentation
  • Powered by a proven, first-in-class technology
  • Best after-sale service

With Ph.D. level scientists and substantial experience and expertise in the discovery of NGP, Creative Biolabs is dedicated to offering P. copri with the best quality and most competitive price. For more detailed information, please feel free to contact us.

Reference

  1. Tett. A.; et al. The Prevotella copri complex comprises four distinct clades underrepresented in westernized populations. Cell host & microbe. 2019, 26(5): 666-79.

For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.

Live Biotherapeutics Drug Discovery

Online Inquiry

For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.

Contact us

Contact us

Copyright © 2022 Creative Biolabs. All Rights Reserved.

Inquiry Basket